Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T.

Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11.

2.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.

3.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

4.

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.

Usmani SZ, Khan I, Chiu C, Foureau D, Druhan LJ, Rigby K, Casneuf T, Sasser AK.

Exp Hematol Oncol. 2018 Feb 7;7:3. doi: 10.1186/s40164-018-0096-7. eCollection 2018.

5.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK.

Br J Haematol. 2019 Feb;184(3):475-479. doi: 10.1111/bjh.15122. Epub 2018 Feb 7. No abstract available.

PMID:
29411874
6.

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.

Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, Ahmadi T, Yan X, Lonial S, Plesner T, Lokhorst HM, van de Donk NWCJ, Clemens PL, Sasser AK.

Blood Adv. 2017 Oct 24;1(23):2105-2114. doi: 10.1182/bloodadvances.2017006866. eCollection 2017 Oct 24.

7.

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW.

Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.

8.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK.

Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.

9.

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.

Casneuf T, Axel AE, King P, Alvarez JD, Werbeck JL, Verhulst T, Verstraeten K, Hall BM, Sasser AK.

Breast Cancer (Dove Med Press). 2016 Feb 3;8:13-27. doi: 10.2147/BCTT.S92414. eCollection 2016.

10.

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.

Erb HH, Langlechner RV, Moser PL, Handle F, Casneuf T, Verstraeten K, Schlick B, Schäfer G, Hall B, Sasser K, Culig Z, Santer FR.

Endocr Relat Cancer. 2013 Aug 23;20(5):677-89. doi: 10.1530/ERC-13-0222. Print 2013 Oct.

11.

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK.

Br J Haematol. 2013 May;161(3):357-66. doi: 10.1111/bjh.12266. Epub 2013 Feb 25.

12.

Transcription regulatory networks in Caenorhabditis elegans inferred through reverse-engineering of gene expression profiles constitute biological hypotheses for metazoan development.

Vermeirssen V, Joshi A, Michoel T, Bonnet E, Casneuf T, Van de Peer Y.

Mol Biosyst. 2009 Dec;5(12):1817-30. doi: 10.1039/B908108a. Epub 2009 Jul 17.

PMID:
19763340
13.

Unraveling transcriptional control in Arabidopsis using cis-regulatory elements and coexpression networks.

Vandepoele K, Quimbaya M, Casneuf T, De Veylder L, Van de Peer Y.

Plant Physiol. 2009 Jun;150(2):535-46. doi: 10.1104/pp.109.136028. Epub 2009 Apr 8.

14.

Quantitative RNA expression analysis with Affymetrix Tiling 1.0R arrays identifies new E2F target genes.

Naouar N, Vandepoele K, Lammens T, Casneuf T, Zeller G, van Hummelen P, Weigel D, Rätsch G, Inzé D, Kuiper M, De Veylder L, Vuylsteke M.

Plant J. 2009 Jan;57(1):184-94. doi: 10.1111/j.1365-313X.2008.03662.x. Epub 2008 Sep 19. Erratum in: Plant J. 2017 Sep;91(6):1129-1130.

15.

In situ analysis of cross-hybridisation on microarrays and the inference of expression correlation.

Casneuf T, Van de Peer Y, Huber W.

BMC Bioinformatics. 2007 Nov 26;8:461.

16.
17.

Nonrandom divergence of gene expression following gene and genome duplications in the flowering plant Arabidopsis thaliana.

Casneuf T, De Bodt S, Raes J, Maere S, Van de Peer Y.

Genome Biol. 2006;7(2):R13. Epub 2006 Feb 20.

18.

Modeling gene and genome duplications in eukaryotes.

Maere S, De Bodt S, Raes J, Casneuf T, Van Montagu M, Kuiper M, Van de Peer Y.

Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5454-9. Epub 2005 Mar 30.

Supplemental Content

Loading ...
Support Center